- Conditions
- Atrial Fibrillation, Atrial Flutter
- Interventions
- Surgical Ablation
- Device
- Lead sponsor
- AtriCure, Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 6
- States / cities
- Hartford, Connecticut • New Haven, Connecticut • Evanston, Illinois + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 601–624
of 8,199
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Heart Diseases, Ventricular Arrhythmia, Ventricular Fibrillation, Death, Sudden, Cardiac, Heart Arrest
- Interventions
- ECG
- Procedure
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 549 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)
- Interventions
- Vericiguat, Placebo
- Drug
- Lead sponsor
- Josef Stehlik
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Salt Lake City, Utah
- Conditions
- Coronary Artery Disease, Diabetes Mellitus
- Interventions
- Percutaneous Coronary Intervention (PCI)
- Procedure
- Lead sponsor
- Gold, Herman K., MD
- Individual
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Duchenne Muscular Dystrophy (DMD)
- Interventions
- SGLT-2 inhibitor, SGLT2 inhibitor
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 8 Years to 18 Years · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Atrial Fibrillation
- Interventions
- Study Watch
- Device
- Lead sponsor
- Verily Life Sciences LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Coronary Artery Disease
- Interventions
- treatment with the Azurion system with Xres5, Azurion with Clairy IQ
- Device · Other
- Lead sponsor
- Philips Clinical & Medical Affairs Global
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 824 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Atlanta, Georgia • New York, New York
- Conditions
- Hypertension (Without Type 2 Diabetes Mellitus), High Blood Pressure, Male, Female, Adult, Cognition, Endothelial Function (Reactive Hyperemia), Oxidative Stress, Diet, Overweight, Body Composition Measurement, Gut Microbiome, Arterial Stiffness, Caucasian Whites, Inflammation, Microvascular Function
- Interventions
- Wild Blueberry, Placebo
- Dietary Supplement
- Lead sponsor
- Georgia State University
- Other
- Eligibility
- 45 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Coronary Artery Disease, Heart Valve Disease
- Interventions
- NO-NUMO™ High Vacuum Body Cavity Drainage System, PVC Chest Tube
- Device
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Cytomegalovirus Disease, Cytomegalovirus Infections, Heart Transplant Infection, Antiviral Toxicity, Neutropenia
- Interventions
- Letermovir
- Drug
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Heart Attack, Cardiac Arrest, Congestive Heart Failure, Atrial Fibrillation, Angina, Deep Vein Thrombosis, Pulmonary Embolism, Respiratory Arrest, Respiratory Failure, Pneumonia, Gastrointestinal Bleed, Stomach Ulcer, Delirium, Stroke, Nerve Injury, Surgical Wound Infection
- Interventions
- Not listed
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 73,952 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Atrial Fibrillation, Cardiac Surgery
- Interventions
- Vivalink wearable life sensors
- Device
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 20 Years to 90 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Heart Failure
- Interventions
- AZD3427, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 10
- States / cities
- Little Rock, Arkansas • Glendale, California • Daytona Beach, Florida + 7 more
- Conditions
- Coronary Artery Disease
- Interventions
- Clopidogrel, Ticagrelor
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Arrhythmias, Cardiac
- Interventions
- Stress reduction treatment (SRT) program
- Behavioral
- Lead sponsor
- Yale University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Cardiac Arrhythmia
- Interventions
- Oxytocin, Saline
- Drug · Other
- Lead sponsor
- William Whang
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Acute Heart Failure
- Interventions
- sacubitril/valsartan (LCZ696), Enalapril, sacubitril/valsartan (LCZ696) matching placebo, enalapril matching placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 887 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 123
- States / cities
- Birmingham, Alabama • Fort Smith, Arkansas • Little Rock, Arkansas + 105 more
- Conditions
- Congenital Heart Diseases, Aortic Valve Disorder
- Interventions
- Cefazolin 25 mg/kg body weight and Vancomycin hydrochloride, Cefazolin 30 mg/kg body weight
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Congenital Heart Disease
- Interventions
- passive range of motion exercise therapy
- Other
- Lead sponsor
- Carelon Research
- Other
- Eligibility
- Up to 35 Days
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 9
- States / cities
- Atlanta, Georgia • Indianapolis, Indiana • Boston, Massachusetts + 6 more
- Conditions
- Hyperlipidemia, Coronary Artery Disease
- Interventions
- red yeast rice, placebo
- Drug
- Lead sponsor
- Chestnut Hill Health System
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- High Risk Pregnancy, Congenital Heart Disease, Fetal Hydrops, Twin Monochorionic Monoamniotic Placenta, Gastroschisis, Fetal Demise, Stillbirth, Fetal Arrhythmia, Long QT Syndrome, Intrauterine Fetal Death, Sudden Infant Death, Pregnancy Loss, Twin Twin Transfusion Syndrome, Birth Defect, Fetal Cardiac Anomaly, Fetal Cardiac Disorder, Fetal Death, Brugada Syndrome, Fetal Tachycardia
- Interventions
- Fetal Magnetocardiogram and Neonatal Electrocardiogram, Substudy only: Maternal/Infant Pharmacogenomic assessment postnatally
- Diagnostic Test · Genetic
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 2
- States / cities
- Madison, Wisconsin • Milwaukee, Wisconsin
- Conditions
- Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC), Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Amyloid Neuropathies, Amyloidosis, Hereditary, Transthyretin-Related, Familial Transthyretin Cardiac Amyloidosis
- Interventions
- Revusiran (ALN-TTRSC), Sterile Normal Saline (0.9% NaCl)
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 41
- States / cities
- Bakersfield, California • Beverly Hills, California • La Mesa, California + 30 more
- Conditions
- Chronic Heart Failure
- Interventions
- carvedilol
- Drug
- Lead sponsor
- Cardiovascular Clinical Sciences Inc
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 54
- States / cities
- Mobile, Alabama • Sierra Vista, Arizona • Anaheim, California + 49 more
- Conditions
- Burnout, Professional
- Interventions
- Apollo Wearable
- Device
- Lead sponsor
- Michelle Thompson
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania